Ibuprofen
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
Ibuprofen: From Pain/Inflammation to Acromesomelic Dysplasia, Hunter-Thompson Type
One-Sentence Summary
Ibuprofen is a widely used NSAID; detailed original-indication and mechanism-of-action data were not available in this evidence pack. The TxGNN model’s top prediction is Acromesomelic Dysplasia, Hunter-Thompson Type, an ultra-rare genetic skeletal disorder, but this is currently supported by 0 clinical trials and 0 publications — the prediction rests entirely on knowledge-graph statistics.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in source data (Ibuprofen is a well-known NSAID generally indicated for pain, fever, and inflammation) |
| Predicted New Indication | Acromesomelic dysplasia, Hunter-Thompson type |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | Not Marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data for Ibuprofen is not available in this evidence pack (original_moa: [Data Gap]), and no original indications were recorded. Based on general pharmacological knowledge, Ibuprofen is a propionic-acid-derivative NSAID that inhibits COX-1/COX-2, reducing prostaglandin synthesis to relieve pain, fever, and inflammation.
Acromesomelic Dysplasia, Hunter-Thompson Type is caused by mutations in the GDF5/CDMP1 gene affecting cartilage morphogenesis signaling — it is a structural/developmental disorder, not a primary inflammatory disease. The only plausible mechanistic bridge is symptomatic: NSAIDs could theoretically relieve secondary joint pain or early-onset osteoarthritis that may accompany this and related skeletal dysplasias, but this would not modify the underlying disease process.
Notably, all seven TxGNN-predicted indications in this evidence pack are rare skeletal/developmental syndromes (brachyolmia variants, pseudoachondroplasia, brachydactyly-syndactyly syndrome, myosclerosis, colobomatous microphthalmia-rhizomelic dysplasia syndrome) clustered at similarly high scores (99.6–99.7%) with identical L5/Hold status and zero trials or literature for any of them. This pattern suggests the model is picking up a broad embedding-space association between NSAIDs and skeletal-disease nodes rather than a disease-specific signal, and none of the seven should be treated as differentiated leads without further mechanistic or clinical evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Safety Considerations
- Drug Interactions: DDI database records 687 total interactions for Ibuprofen. Representative interactions from this evidence pack:
- Major: Acetylsalicylic acid (Aspirin)
- Moderate: Acetohexamide, Aprepitant, Balsalazide, Betamethasone, Budesonide, Chlorpropamide, Dexamethasone, Dexfenfluramine, Exenatide, Fenfluramine, Glimepiride, Glipizide, Glyburide, Hydrocortisone, Kanamycin, Levofloxacin
- Minor: Famotidine, Ranitidine, Cimetidine
Detailed prescribing warnings and contraindications are not yet available in this evidence pack; please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: All seven candidate indications, including the top-ranked Acromesomelic Dysplasia, Hunter-Thompson Type, are L5 (model-prediction-only) with zero supporting trials or literature and a weak-to-absent mechanistic rationale. Combined with a blocking data gap on TFDA label warnings/contraindications and the drug’s unmarketed status in Taiwan (0 registrations), this candidate cannot proceed to safety evaluation.
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — currently a blocking data gap (DG001)
- Confirmed DrugBank mechanism-of-action data (DG002)
- Preclinical or case-level evidence directly linking Ibuprofen to any of the seven predicted rare skeletal disorders
- Clarification of Taiwan market/import status given the drug is currently not marketed
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.